Non-small cell lung carcinoma genotype(s)-ALK Posts on Medivizor
Navigation Menu

Non-small cell lung carcinoma genotype(s)-ALK Posts on Medivizor

Durvalumab as third-line treatment in advanced lung cancer – does gene expression affect response?

Posted by on Jul 21, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies.  They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...

Read More

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

Posted by on Jan 12, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if the medication brigatinib (Alunbrig) is better than crizotinib (Xalkori) in treating patients with lung cancer. The study found that survival was significantly longer in patients who were treated with brigatinib compared to those treated with crizotinib. Some background Brigatinib and crizotinib are a...

Read More

Brigatinib for the treatment of previously treated ALK-positive non-small-cell lung cancer

Posted by on Aug 2, 2017 in Lung cancer | 0 comments

In a nutshell This trial examined a new therapy, brigatinib (Alunbrig), in treating patients with ALK-positive non-small-cell lung cancer (NSCLC) that has progressed passed initial treatments. The authors concluded that brigatinib was safe and effective at treating this type of cancer. Some background One type of NSCLC is caused by genetic...

Read More

Looking for patients with non-small cell lung cancer to test the effectiveness of ceritinib in treating brain metastases

Posted by on Jul 11, 2017 in Lung cancer | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of ceritinib (Zykadia) treatment, in treating ALK positive non-small cell lung cancer (NSCLC) with brain metastases and/or leptomeningeal carcinomatosis. The primary outcome will be measured by the disease response to treatment. The details Some lung cancers are associated...

Read More

Updated guidelines for the treatment of stage IV NSCLC

Posted by on May 30, 2016 in Lung cancer | 0 comments

In a nutshell The American Society of Clinical Oncology (ASCO) gathered a panel of experts to update guidelines on systemic therapy (such as chemotherapy) for stage 4 non-small cell lung cancer (NSCLC). They provided updated guidelines with recommendations for first, second and third-line systemic therapy as well as targeted therapy.  Some...

Read More

Ceritinib and crizotinib in ALK-mutated lung cancer patients. A perfect combination?

Posted by on Sep 5, 2015 in Lung cancer | 0 comments

In a nutshell This study looked at whether crizotinib and then ceritinib helped improve survival rates in patients with lung cancer. Some background Anaplastic lymphoma kinase (ALK) is an important protein involved in cell development. It is estimated that genetic changes that alter the function of ALK are found in 3-5% of all non-small cell lung...

Read More